A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma

Official Title

An Open-Label, Randomized, Multicentre, Phase Ib/II Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma

Summary:

This study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of mosunetuzumab in combination with polatuzumab vedotin in participants with diffuse large B-cell lymphoma (DLBCL) and in participants with follicular lymphoma (FL). It will consist of a dose finding portion followed by an expansion phase for second line or later (2L+) participants with relapsed or refractory (R/R) DLBCL and 2L+ R/R FL.

Trial Description

Primary Outcome:

  • Complete Response (CR) Rate Based on Positron Emission Tomography-Computed Tomography (PET-CT), as Assessed Using Standard Criteria for non-Hodgkin Lymphoma (NHL)
  • Maximum Tolerated Dose (MTD) of Mosunetuzumab in Combination with Polatuzumab Vedotin
  • Recommended Phase II Dose of Mosunetuzumab in Combination with Polatuzumab Vedotin
  • Percentage of Participants with Adverse Events (AE)
Secondary Outcome:
  • CR Rate Based on PET-CT, as Assessed Using Standard Criteria for NHL
  • CR Rate Based on CT Only, as Assessed Using Standard Criteria for NHL
  • Objective Response Rate (ORR), Defined as CR or PR, Based on PET-CT as Assessed Using Standard Criteria for NHL
  • Best ORR (CR or PR at any Time) Based on PET-CT or CT Only, as Assessed Using Standard Criteria for NHL
  • Duration of Response (DOR) as Assessed Using Standard Criteria for NHL
  • Progression-Free Survival (PFS) as Assessed Using Standard Criteria for NHL
  • Event-Free Survival (EFS) as Assessed Using Standard Criteria for NHL
  • Overall Survival (OS)
  • Time to Deterioration in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Physical Functioning and Fatigue
  • Time to Deterioration in Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) Subscale
  • Anti-Drug Antibodies (ADAs) to Mosunetuzumab
  • ADAs to Polatuzumab Vedotin
  • Mosunetuzumab Serum Concentration

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society